All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Research Article Open Access
FORMULATION DEVELOPMENT AND STABILIZATION OF QUINAPRIL IN LOW DOSE PILL
Hypertension is the most common risk factor for cardiovascular diseases, stroke and renal failure. A recent guideline by the Joint National Commission (JNC8 guidelines) recommended both angiotensin-converting enzyme (ACE) inhibitors & calcium channel blockers (CCB) as first-line drugs, in addition to diuretics. The increasing prevalence of hypertension leads to boom in the medicinal sector for the effective medications, fixed dose & multiple dose combinations are studied & provided to patient’s leads to the several adverse effects to patients therefore Low Dose Single Pill Therapy got recognition. Quinapril is efficacious drug of BCS Class I (high soluble, high permeable), but it prone to degradation reactions like hydrolysis, oxidation & cyclization easily to diketopiperazine impurity. Formation of diketopiperazine is a major stability issue to the potent ACE inhibitors. Therefore a stable formulation designing is a basic challenge in the formulation of the quinapril tablets. Degradation can be observed in the tablets at processing, storage & packing stage on elevated temperature or moisture to the active moiety & formulation. Therefore formulating & is quite challenging. Formulation designed contains a magnesium carbonate as stabilizer in different process optimization which prevent API to form impurity. The optimized formulation results found are satisfactory with accelerated stability study